Construction of gastric cancer patient-derived organoids and their utilization in a comparative study of clinically used paclitaxel nanoformulations
文献类型：期刊论文
| 作者 | Zou,Jiale1,2; Wang,Shuang2; Chai,Ningli1; Yue,Hua2; Ye,Peng2; Guo,Peilin2,3; Li,Feng2,3; Wei,Bo4; Ma,Guanghui2,3; Wei,Wei2,3 |
| 刊名 | Journal of Nanobiotechnology
 |
| 出版日期 | 2022-05-18 |
| 卷号 | 20期号:1 |
| 关键词 | Gastric cancer Patient-derived organoids Nanoformulation Albumin-bound paclitaxel Liposomal paclitaxel |
| DOI | 10.1186/s12951-022-01431-8 |
| 英文摘要 | AbstractBackgroundGastric cancer (GC) is a highly heterogeneous disease with many different histological and molecular subtypes. Due to their reduced systemic adverse effects, nanoformulation agents have attracted increasing attention for use in the treatment of GC patients in the clinic. To improve therapeutic outcomes, it is vitally necessary to provide individual medication references and guidance for use of these nanoformulations, and patient-derived organoids (PDOs) are promising models through which to achieve this goal.ResultsUsing an improved enzymatic digestion process, we succeeded in constructing GC PDOs from surgically resected tumor tissues and endoscopic biopsies from GC patients; these PDOs closely recapitulated the histopathological and genomic features of the corresponding primary tumors. Next, we chose two representative paclitaxel (PTX) nanoformulations for comparative study and found that liposomal PTX outperformed albumin-bound PTX in killing GC PDOs at both the transcriptome and cellular levels. Our results further showed that the different distributions of liposomal PTX and albumin-bound PTX in PDOs played an essential role in the distinct mechanisms through which they kill PDOs. Finally, we constructed patient-derived xenografts model in which we verified the above distinct therapeutic outcomes via an intratumoral administration route.ConclusionsThis study demonstrates that GC PDOs are reliable tools for predicting nanoformulation efficacy.Graphical Abstract |
| 语种 | 英语 |
| 出版者 | BioMed Central |
| WOS记录号 | BMC:10.1186/S12951-022-01431-8 |
| 源URL | [http://ir.ipe.ac.cn/handle/122111/49949]  |
| 专题 | 中国科学院过程工程研究所 |
| 通讯作者 | Ma,Guanghui; Wei,Wei; Linghu,Enqiang |
| 作者单位 | 1.Chinese PLA General Hospital; Department of Gastroenterology and Hepatology, The First Medical Centre 2.Chinese Academy of Sciences; State Key Laboratory of Biochemical Engineering, Institute of Process Engineering 3.University of Chinese Academy of Sciences; School of Chemical Engineering 4.Chinese PLA General Hospital; Department of General Surgery, The First Medical Centre |
| 推荐引用方式 GB/T 7714 | Zou,Jiale,Wang,Shuang,Chai,Ningli,et al. Construction of gastric cancer patient-derived organoids and their utilization in a comparative study of clinically used paclitaxel nanoformulations[J]. Journal of Nanobiotechnology,2022,20(1). |
| APA | Zou,Jiale.,Wang,Shuang.,Chai,Ningli.,Yue,Hua.,Ye,Peng.,...&Linghu,Enqiang.(2022).Construction of gastric cancer patient-derived organoids and their utilization in a comparative study of clinically used paclitaxel nanoformulations.Journal of Nanobiotechnology,20(1). |
| MLA | Zou,Jiale,et al."Construction of gastric cancer patient-derived organoids and their utilization in a comparative study of clinically used paclitaxel nanoformulations".Journal of Nanobiotechnology 20.1(2022). |
入库方式： OAI收割
来源：过程工程研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。